Kiadis Pharma N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 27 nov 2015 - 07:00

Statutaire naam Kiadis Pharma N.V.

Titel Kiadis Pharma Interim Management Statement for the nine months ended 30 September 2015

Bericht Amsterdam, The Netherlands, November 27, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its Interim Management Statement for the nine months ended 30 September 2015. Operational review Kiadis Pharma continued to make good progress in developing its lead product ATIR101™ for blood cancer: • Full enrolment of the ongoing Phase II clinical study (CR-AIR-007) with ATIR101™ has been accomplished. The primary endpoint for the last patient in this trial will be reached at the end of Q1, 2016 and top-line results will follow at the beginning of Q2, 2016. • Another study (CR-AIR-008), testing repeat dose administration of ATIR101™ in parallel with the ongoing Phase II trial, has been initiated and has enrolled its first patient. • Establishing a closed manufacturing process that allows for automation which is advancing according to plan. Interim financial results In the first nine months of 2015, the Company did not generate any revenues. The net loss for the nine months ended 30 September 2015 came at a level of €13.1 million. Expenses and net results are in line with management expectations. The Company ended the first nine months of 2015 with €31.3 million in cash and cash equivalents and an equity position of €29.1 million. Kiadis Pharma listed its shares via an IPO on Euronext Amsterdam and Brussels on 2 July 2015. The gross proceeds from the IPO came to a total of €34.7 million and net proceeds came to a total of €31.2 million. The financial information in this press release has not been audited nor reviewed by the external auditor. About ATIR101™ For patients suffering from blood cancers, an allogeneic hematopoietic stem cell transplantation (HSCT) is generally regarded as the most effective curative approach. During an HSCT treatment, the bone mar

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201511260000000008_151127 Kiadis Pharma Q3 statement 2015 final.pdf (opens in a new window)

Datum laatste update: 28 juli 2024